• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Deep Generative AI for Multi-Target Therapeutic Design: Toward Self-Improving Drug Discovery Framework.用于多靶点治疗设计的深度生成式人工智能:迈向自我改进的药物发现框架。
Int J Mol Sci. 2025 Nov 26;26(23):11443. doi: 10.3390/ijms262311443.
2
AI-Driven Polypharmacology in Small-Molecule Drug Discovery.小分子药物发现中的人工智能驱动多药理学
Int J Mol Sci. 2025 Jul 21;26(14):6996. doi: 10.3390/ijms26146996.
3
Advanced AI and ML frameworks for transforming drug discovery and optimization: With innovative insights in polypharmacology, drug repurposing, combination therapy and nanomedicine.用于变革药物发现与优化的先进人工智能和机器学习框架:具备在多药理学、药物再利用、联合疗法和纳米医学方面的创新见解。
Eur J Med Chem. 2025 Feb 15;284:117164. doi: 10.1016/j.ejmech.2024.117164. Epub 2024 Dec 13.
4
Artificial intelligence to deep learning: machine intelligence approach for drug discovery.人工智能到深度学习:药物发现的机器智能方法。
Mol Divers. 2021 Aug;25(3):1315-1360. doi: 10.1007/s11030-021-10217-3. Epub 2021 Apr 12.
5
Generative AI for the Design of Molecules: Advances and Challenges.
J Chem Inf Model. 2025 Dec 8;65(23):12668-12690. doi: 10.1021/acs.jcim.5c02234. Epub 2025 Nov 18.
6
Harnessing AI-driven reverse docking in drug discovery: a comprehensive review of opportunities, challenges, and emerging trends.利用人工智能驱动的反向对接进行药物发现:机遇、挑战及新趋势的全面综述
J Mol Model. 2025 Aug 25;31(9):256. doi: 10.1007/s00894-025-06480-y.
7
AI for targeted polypharmacology: The next frontier in drug discovery.人工智能在靶向多药理学中的应用:药物发现的下一个前沿领域。
Curr Opin Struct Biol. 2024 Feb;84:102771. doi: 10.1016/j.sbi.2023.102771. Epub 2024 Jan 11.
8
Artificial Intelligence for Autonomous Molecular Design: A Perspective.人工智能自主分子设计:一个视角。
Molecules. 2021 Nov 9;26(22):6761. doi: 10.3390/molecules26226761.
9
Role of artificial intelligence in cancer drug discovery and development.人工智能在癌症药物发现与开发中的作用。
Cancer Lett. 2025 Sep 1;627:217821. doi: 10.1016/j.canlet.2025.217821. Epub 2025 May 23.
10
Generative chemistry: drug discovery with deep learning generative models.生成化学:用深度学习生成模型进行药物发现。
J Mol Model. 2021 Feb 4;27(3):71. doi: 10.1007/s00894-021-04674-8.

引用本文的文献

1
Artificial intelligence driven protein design and sustainable nanomedicine for advanced theranostics.人工智能驱动的蛋白质设计与可持续纳米医学用于先进的诊疗。
Bioact Mater. 2026 Jan 30;60:425-455. doi: 10.1016/j.bioactmat.2026.01.036. eCollection 2026 Jun.

本文引用的文献

1
Guided multi-objective generative AI to enhance structure-based drug design.引导式多目标生成式人工智能增强基于结构的药物设计。
Chem Sci. 2025 May 29. doi: 10.1039/d5sc01778e.
2
DeepDTAGen: a multitask deep learning framework for drug-target affinity prediction and target-aware drugs generation.DeepDTAGen:用于药物-靶点亲和力预测和靶点导向药物生成的多任务深度学习框架。
Nat Commun. 2025 May 30;16(1):5021. doi: 10.1038/s41467-025-59917-6.
3
ASKCOS: Open-Source, Data-Driven Synthesis Planning.ASKCOS:开源、数据驱动的合成规划。
Acc Chem Res. 2025 Jun 3;58(11):1764-1775. doi: 10.1021/acs.accounts.5c00155. Epub 2025 May 21.
4
Computational modeling approaches and regulatory pathways for drug combinations.药物组合的计算建模方法和调控途径。
Drug Discov Today. 2025 May;30(5):104345. doi: 10.1016/j.drudis.2025.104345. Epub 2025 Mar 28.
5
CardioGenAI: a machine learning-based framework for re-engineering drugs for reduced hERG liability.CardioGenAI:一种基于机器学习的框架,用于重新设计药物以降低hERG风险。
J Cheminform. 2025 Mar 5;17(1):30. doi: 10.1186/s13321-025-00976-8.
6
Human-in-the-loop active learning for goal-oriented molecule generation.用于目标导向分子生成的人工参与式主动学习
J Cheminform. 2024 Dec 9;16(1):138. doi: 10.1186/s13321-024-00924-y.
7
Structure-based drug design with equivariant diffusion models.基于结构的药物设计与等变扩散模型
Nat Comput Sci. 2024 Dec;4(12):899-909. doi: 10.1038/s43588-024-00737-x. Epub 2024 Dec 9.
8
Addressing high-performance data sparsity in metasurface inverse design using multi-objective optimization and diffusion probabilistic models.
Opt Express. 2024 Nov 4;32(23):40869-40885. doi: 10.1364/OE.537389.
9
Automated design of multi-target ligands by generative deep learning.基于生成式深度学习的多靶标配体自动化设计。
Nat Commun. 2024 Sep 11;15(1):7946. doi: 10.1038/s41467-024-52060-8.
10
Ligand-Based Approach for Multi-Target Drug Discovery: PTML Modeling of Triple-Target Inhibitors.基于配体的多靶点药物发现方法:三靶点抑制剂的PTML建模
Curr Top Med Chem. 2024 Aug 21. doi: 10.2174/0115680266325897240815112505.

用于多靶点治疗设计的深度生成式人工智能:迈向自我改进的药物发现框架。

Deep Generative AI for Multi-Target Therapeutic Design: Toward Self-Improving Drug Discovery Framework.

作者信息

Kang Soo Im, Shin Jae Hong, Wu Benjamin M, Choi Hak Soo

机构信息

Institute for Cancer Genetics, Columbia University Irving Medical Research Center, 1130 St. Nicholas Ave, New York, NY 10032, USA.

Qunova Computing Inc., Chrono Building Suite 501, 316 Gajeongro, Daejeon 34130, Republic of Korea.

出版信息

Int J Mol Sci. 2025 Nov 26;26(23):11443. doi: 10.3390/ijms262311443.

DOI:10.3390/ijms262311443
PMID:41373598
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12691712/
Abstract

Multi-target drug design represents a paradigm shift in tackling the complexity and heterogeneity of diseases such as cancer. Conventional single-target therapies frequently face limitations due to network redundancy, pathway compensation, and adaptive resistance mechanisms. In contrast, deep generative models, empowered by advanced artificial intelligence algorithms, provide scalable and versatile platforms for the generation and optimization of small molecules with activity across multiple therapeutic targets. This review provides a comprehensive overview of the recent landscape of AI-driven deep generative modeling for multi-target drug discovery, highlighting breakthroughs in model architectures, molecular representations, and goal-directed optimization strategies. We also examine the emergence of self-improving learning systems, closed-loop frameworks that iteratively refine molecular candidates through integrated feedback, as a transformative approach to adaptive drug design. Finally, key challenges, current limitations, and emerging trends are discussed to guide the evolution of next-generation intelligent and autonomous drug discovery pipelines for multi-target therapeutics.

摘要

多靶点药物设计代表了应对癌症等疾病的复杂性和异质性方面的范式转变。传统的单靶点疗法由于网络冗余、通路补偿和适应性耐药机制,常常面临局限性。相比之下,由先进人工智能算法赋能的深度生成模型,为生成和优化具有跨多个治疗靶点活性的小分子提供了可扩展且通用的平台。本综述全面概述了用于多靶点药物发现的人工智能驱动深度生成建模的最新进展,重点介绍了模型架构、分子表示和目标导向优化策略方面的突破。我们还研究了自我改进学习系统的出现,即通过集成反馈迭代优化分子候选物的闭环框架,作为适应性药物设计的变革性方法。最后,讨论了关键挑战、当前局限性和新兴趋势,以指导用于多靶点治疗的下一代智能自主药物发现流程的发展。